In vivo CRISPR editing with no detectable genome-wide off-target mutations

Pınar Akçakaya(AstraZeneca (Sweden)), Maggie Bobbin(Center for Cancer Research), Jimmy A. Guo(Center for Cancer Research), Jose Malagon-Lopez(Harvard University), Kendell Clement(Massachusetts General Hospital), Sara P. Garcia(Center for Cancer Research), Mick D. Fellows(AstraZeneca (United Kingdom)), Michelle J. Porritt(AstraZeneca (Sweden)), Mike Firth(AstraZeneca (United Kingdom)), Alba Carreras(AstraZeneca (Sweden)), Tania Baccega(Istituti di Ricovero e Cura a Carattere Scientifico), Frank Seeliger(AstraZeneca (Sweden)), Mikael Bjursell(AstraZeneca (Sweden)), Shengdar Q. Tsai(Center for Cancer Research), Nathalie T. Nguyen(Center for Cancer Research), Roberto Nitsch(AstraZeneca (Sweden)), Lorenz M. Mayr(AstraZeneca (Sweden)), Luca Pinello(Center for Cancer Research), Mohammad Bohlooly‐Y(AstraZeneca (Sweden)), Martin J. Aryee(Harvard University), Marcello Maresca(AstraZeneca (Sweden)), J. Keith Joung(Massachusetts General Hospital)
Nature
September 1, 2018
10.1038/s41586-018-0500-9
Cited by 321Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis